Clinical trials show weight loss outcomes of up to 15%, with additional benefits including reduced A1C levels and cardiovascular improvements Key Benefits of GLP-1 Therapies: Enhanced insulin sensitivity Lower blood sugar levels Reduced visceral fat and improved lipid profiles Improved cardiovascular health Decreased inflammation linked to chronic disease Source: Glucagon-like peptide 1 in health and disease
Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease
Earlier this year, the FDA approved Ozempic as the only GLP-1 drug that reduces the risk of worsening kidney disease
Older adults and perimenopause
Ponirakis G, Abdul-Ghani MA, Jayyousi A, Zirie MA, Qazi M, Almuhannadi H, Petropoulos IN, Khan A, Gad H, Migahid O, Megahed A, Al-Mohannadi S, AlMarri F, Al-Khayat F, Mahfoud Z, Al Hamad H, Ramadan M, DeFronzo R, Malik RA (2021) Painful diabetic neuropathy is associated with increased nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control
Lilly also has broader ambitions for orforglipron beyond obesity